News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,479 Results
Type
Article (102)
Company Profile (1)
Press Release (1376)
Section
Business (484)
Career Advice (2)
Deals (124)
Drug Development (168)
FDA (12)
Job Trends (23)
News (722)
Policy (22)
Tag
Academia (1)
Alliances (113)
Alzheimer's disease (16)
Antibody-drug conjugate (ADC) (2)
Approvals (11)
Artificial intelligence (1)
Autoimmune disease (1)
Bankruptcy (5)
Best Places to Work (16)
Breast cancer (1)
Cancer (17)
Career advice (2)
Cell therapy (3)
Clinical research (158)
Collaboration (6)
C-suite (10)
Data (16)
Depression (2)
Diagnostics (8)
Earnings (38)
Editorial (1)
Events (130)
Executive appointments (6)
FDA (16)
Funding (35)
Gene therapy (1)
Government (2)
Healthcare (35)
Immunology and inflammation (1)
IPO (59)
Job creations (3)
Job search strategy (2)
Layoffs (1)
Legal (7)
Lung cancer (4)
Manufacturing (3)
Medical device (17)
Medtech (18)
Mergers & acquisitions (63)
Neurodegenerative disease (2)
Neuroscience (18)
NextGen: Class of 2026 (31)
Ovarian cancer (4)
Parkinson's disease (1)
Patient recruitment (4)
People (223)
Pharmaceutical (3)
Phase 1 (56)
Phase 2 (94)
Phase 3 (23)
Pipeline (10)
Postmarket research (3)
Preclinical (24)
Press Release (5)
Radiopharmaceuticals (1)
Rare diseases (4)
Real estate (5)
Regulatory (21)
Research institute (3)
Resumes & cover letters (1)
RNA editing (1)
Schizophrenia (1)
Series A (14)
Series B (9)
Startups (108)
Date
Today (2)
Last 7 days (3)
Last 30 days (6)
Last 365 days (82)
2026 (9)
2025 (87)
2024 (99)
2023 (65)
2022 (82)
2021 (142)
2020 (142)
2019 (90)
2018 (46)
2017 (45)
2016 (41)
2015 (45)
2014 (27)
2013 (30)
2012 (41)
2011 (50)
2010 (67)
Location
Africa (2)
Alabama (1)
Arizona (1)
Arkansas (1)
Asia (181)
Australia (5)
California (27)
Canada (5)
Colorado (3)
Connecticut (2)
Europe (233)
Indiana (1)
Japan (2)
Kansas (1)
Maryland (3)
Massachusetts (21)
Minnesota (1)
New Jersey (5)
New Mexico (1)
New York (3)
North Carolina (9)
Northern California (12)
Ohio (2)
Pennsylvania (2)
Rhode Island (1)
South America (1)
Southern California (13)
Texas (3)
United States (89)
Utah (2)
Washington State (1)
Wisconsin (2)
1,479 Results for "arrivo bioventures".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition
January 10, 2025
·
4 min read
Press Releases
Arrivo BioVentures Begins Phase 1 Study of SP-624, the First Potential Treatment Specifically for Women with Major Depressive Disorder
October 10, 2024
·
3 min read
Drug Development
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
April 16, 2024
·
2 min read
Drug Development
Arrivo BioVentures Announces SP-624 Demonstrated Robust Efficacy in Females With Major Depressive Disorder in Phase 2 Study
Arrivo BioVentures today announced preliminary results from its SP-624-201 study, a randomized, placebo-controlled Phase 2 clinical trial of SP-624 in 319 patients with major depressive disorder (MDD).
October 17, 2022
·
5 min read
Drug Development
Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder
Arrivo BioVentures announced today that the company has closed enrollment of a phase 2 clinical study with its most advanced program, SP-624, after having enrolled more than 300 patients with major depressive disorder.
May 26, 2022
·
2 min read
Business
Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor
Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor.
January 3, 2024
·
3 min read
Press Releases
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
November 3, 2025
·
2 min read
Bio NC
ArrivoBio Raises $45M in Series B Financing to Advance Pipeline
Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $100M.
November 29, 2023
·
3 min read
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.
April 17, 2024
·
4 min read
Press Releases
Capital BioVentures Announces Inaugural Cohort for Ottawa Biotech Accelerator Program
December 3, 2024
·
6 min read
1 of 148
Next
